Health Care Equipment

IDEXX Labs

Jefferies Reiterates Buy Rating on IDEXX Laboratories

Analysts Lower IDXX Lab's Target Price Estimate

IDEXX Labs released FY2026 Q1 earnings on May 5 Pre-Market (EST), actual revenue USD 1.141 B (forecast USD 1.109 B), actual EPS USD 3.47 (forecast USD 3.4124)

IDEXX Laboratories Reports First Quarter Earnings

IDEXX Labs to Release FY2026 Q1 Earnings on May 5, Pre-Market EST; Forecast Revenue USD 1.109 B, EPS USD 3.4152

Krilogy Financial LLC 大幅减持 IDEXX Laboratories 持股

Third View Private Wealth LLC Invests in IDEXX Laboratories As Insiders Sell Heavily

IDEXX Launches Early Screening Panel for Canine Lymphoma in the UK

Spire Wealth Management Increases Holdings in IDEXX Stock Significantly

Russell Investments Reduced Holdings in IDEXX Laboratories in Q3

Nimrata Hunt, Executive Vice President of IDEXX Laboratories Inc., Disposed of Common Stock

IDEXX Laboratories Outlines Growth Strategy at Raymond James 47th Annual Institutional Investor Conference

IDEXX Laboratories Reports Q4 Earnings and Outlines 2026 Growth Goals

IDEXX Announces 10.4% Revenue Growth in FY2025

IDEXX Laboratories Inc. EVP Sells Company Common Stock

Jensen Investment Management Reduces Holding of IDEXX, Geode Capital Management Increases Holding

IDEXX Laboratory Stock Ratings Show Mixed Sentiment

IDEXX Labs released FY2025 Annual Earnings on February 2, Pre-Market EST: Actual Revenue USD 4.304 B (Forecast USD 4.285 B), Actual EPS USD 13.08 (Forecast USD 12.9291)

IDEXX Labs released FY2025 Q4 earnings on February 2, Pre-Market (EST), actual revenue USD 1.091 B (forecast USD 1.072 B), actual EPS USD 3.08 (forecast USD 2.9375)

IDEXX Labs to Release FY2025 Q4 Earnings on February 2, 2026, During-Market EST; Forecast Revenue USD 1.072 B, EPS USD 2.9385

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IDXX Laboratories (IDXX.US) Q4 2025 Earnings Conference Call

IDXX Laboratories (IDXX.US) Q3 2025 Earnings Conference Call

IDXX Laboratories (IDXX.US) Q2 2025 Earnings Conference Call

IDXX

ARKG

IDNA

SBIO

LABU

IDEXX Laboratories Inc. (IDXX) shares rose 3.21% to $545.79 on a mixed trading day, while the Dow Jones increased by 0.32% and the S&P 500 fell by 0.07%. Despite the gain, IDXX remains 29.12% below its 52-week high of $769.98. Competitors like Johnson & Johnson, Medtronic, and Boston Scientific also saw stock increases, with Boston Scientific leading at 6.15%. Trading volume for IDXX was 633,490, surpassing its 50-day average of 559,521.

MarketWatch Automated

Ark Genomic Revolution ETF

iShares Genomics Immunology and Healthcare ETF

SPDR S&P Biotech

iShares US Healthcare Providers

iShares Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

Health Care Select Sector SPDR

iShares US Medical Devices

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

IDEXX Laboratories Inc. Stock Outperforms Competitors On Strong Trading Day

Elyxium Wealth LLC has invested $3.67 billion in IDEXX Laboratories, acquiring 5,419,507 shares, which now represent 54.3% of its portfolio. Other institutional investors have also increased their stakes in IDEXX. The company's stock opened at $528.79, with a market cap of $41.71 billion and a P/E ratio of 38.94. IDEXX reported a quarterly EPS of $3.47, exceeding estimates, and has set FY 2026 guidance at 14.450-14.900 EPS.

Market Beat

Bank of NY Mellon

Invesco

Principal Financial

Citigroup

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX

Joseph L Hooley, a Board Member at IDEXX Laboratories, acquired stock options for 525 shares at an exercise price of $533.92, valued at $771, as reported in a recent SEC filing. IDEXX shares are currently trading at $535.39, reflecting a 0.47% increase. The company has shown a revenue growth rate of 14.26% and maintains a high gross margin of 63.35%. However, it faces challenges with a debt-to-equity ratio of 0.71, indicating increased financial risk.

benzinga_article

In A Strategic Move, Joseph L Hooley Acquires IDEXX Laboratories Stock Options Worth $771: Enhancing Value

Sam Samad, a Board Member at IDEXX Laboratories, exercised stock options for 0 shares at an exercise price of $0.0, as disclosed in a recent SEC filing. IDEXX shares are currently trading at $532.0, reflecting a 0.47% increase. The company reported a revenue growth rate of 14.26% and a gross margin of 63.35%, indicating strong financial performance despite a higher debt-to-equity ratio of 0.71.

Engaging In Insider Activity, Sam Samad At IDEXX Laboratories Exercises Options Worth $0

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day | IDXX Stock News

StockTitan

Stifel Financial

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day | IDXX Stock News

IDEXX Labs(IDXX.US)

IDEXX Laboratories Inc. Stock Outperforms Competitors On Strong Trading Day

Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX

In A Strategic Move, Joseph L Hooley Acquires IDEXX Laboratories Stock Options Worth $771: Enhancing Value

Engaging In Insider Activity, Sam Samad At IDEXX Laboratories Exercises Options Worth $0

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day | IDXX Stock News